Vancomycin: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
| Line 1: | Line 1: | ||
= |
= Indications = |
||
== Indications == |
|||
* Suspected or confirmed MRSA |
* Suspected or confirmed MRSA |
||
= Dosing = |
|||
* Common dose |
* Common dose |
||
| Line 14: | Line 12: | ||
** 15-20 for high-risk infections such as osteomyelitis, meningitis, and bacteremia |
** 15-20 for high-risk infections such as osteomyelitis, meningitis, and bacteremia |
||
= Adverse Reactions = |
|||
== Renal Failures == |
|||
* Risk factors |
* Risk factors |
||
| Line 30: | Line 28: | ||
* Mechanism of injury: oxidative stress in the proximal tubular cells |
* Mechanism of injury: oxidative stress in the proximal tubular cells |
||
== Red Man Syndrome == |
|||
* Rash, pruritis, and hypotension, with onset of vancomycin, resolves on stopping |
* Rash, pruritis, and hypotension, with onset of vancomycin, resolves on stopping |
||
| Line 36: | Line 34: | ||
* Histamine-mediated |
* Histamine-mediated |
||
* Can decrease dose or prolong infusion, prophylactic antihistamines |
* Can decrease dose or prolong infusion, prophylactic antihistamines |
||
[[Category:Antibiotics]] |
|||
Revision as of 03:43, 15 August 2019
Indications
- Suspected or confirmed MRSA
Dosing
- Common dose
- 15mg/kg/dose with timing based on renal function (q12h if normal)
- Titrate based on serum trough drawn within hour before fourth dose
- Target trough
- 10-15 for low-risk infections
- 15-20 for high-risk infections such as osteomyelitis, meningitis, and bacteremia
Adverse Reactions
Renal Failures
- Risk factors
- Prolonged courses >21 days
- Higher trough
- Concomitant nephrotoxic medication
- Older age
- CKD/AKI
- Liver disease
- Peritonitis
- Neutropenia
- Male sex
- Mechanism of injury: oxidative stress in the proximal tubular cells
Red Man Syndrome
- Rash, pruritis, and hypotension, with onset of vancomycin, resolves on stopping
- Very high incidence previously
- Histamine-mediated
- Can decrease dose or prolong infusion, prophylactic antihistamines
References
- ^ Michael J Rybak, Jennifer Le, Thomas P Lodise, Donald P Levine, John S Bradley, Catherine Liu, Bruce A Mueller, Manjunath P Pai, Annie Wong-Beringer, John C Rotschafer, Keith A Rodvold, Holly D Maples, Benjamin M Lomaestro. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020. doi:10.1093/ajhp/zxaa036.
